Corpus Intelligence IC Memo — THE UNITY HOSPITAL OF ROCHESTER 2026-04-26 03:43 UTC
IC Memo — THE UNITY HOSPITAL OF ROCHESTER
Investment Committee Memorandum | NY | 283 beds | Grade B | EBITDA uplift $42.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

THE UNITY HOSPITAL OF ROCHESTER

CCN 330226 | MONROE, NY | 283 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

THE UNITY HOSPITAL OF ROCHESTER is a 283-bed suburban community hospital in MONROE, NY with $571.5M in net patient revenue and a -17.8% operating margin. The hospital serves a payer mix of 16.5% Medicare, 1.7% Medicaid, and 81.7% commercial.

Thesis: Undervalued. Our ML models identify $42.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -17.8% to -10.4% (+736bps).

Net Revenue HCRIS$571.5M
Current EBITDA COMPUTED$-101.7M
Operating Margin COMPUTED-17.8%
Occupancy HCRIS110.8%
Revenue / Bed COMPUTED$2.0M
Net-to-Gross HCRIS41.8%
Distress Probability ML34.2%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
92
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -17.8% places it below the state median. Among 92 size-comparable peers (142-566 beds), the median margin is -17.6%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (142-566), prioritizing same-state peers. 92 hospitals in the comp set.

HospitalStateBedsRevenueMargin
THE UNITY HOSPITAL OF ROCHESTE (Target)NY283$571.5M-17.8%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
LENOX HILL HOSPITALNY415$1.32B-35.1%
BELLEVUE HOSPITAL CENTERNY527$1.31B-17.6%
STATEN ISLAND UNIVERSITY HOSPINY515$1.23B-34.6%
JACOBI MEDICAL CENTERNY440$1.14B-16.8%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
ROCHESTER GENERAL HOSPITALNY470$1.05B-27.9%
NYC HEALTH+HOSPITAL/KINGS COUNNY381$1.03B-15.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $42.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$12.0M+210bp18mo
Cost to Collect4.5%2.5%$11.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$11.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$7.0M+122bp9mo
Clean Claim Rate88.0%96.0%$366K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$12.0M
Cost to Collect
$11.4M
Denial Rate Reduction
$11.3M
A/R Days Reduction
$7.0M
Clean Claim Rate
$366K
Total EBITDA Uplift$42.1M
Current EBITDA$-101.7M
+ RCM Uplift+$42.1M
Pro Forma EBITDA$-59.6M
Current Margin-17.8%
Pro Forma Margin-10.4%
WC Released (1x)$21.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-156.4M$-249.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-156.4M$-325.7M0.00x-100.0%
Bull Case9.0x11.0x$-140.8M$-237.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-140.8M$-300.8M0.00x-100.0%
Bear Case11.0x10.0x$-172.0M$-409.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-172.0M$-506.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 92 hospitals with 142-566 beds
  • Same-state prioritization (n=93)
  • Comp margins: P25=-27.9% / P50=-17.6% / P75=-9.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.